TITLE

Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn’s disease

AUTHOR(S)
Puli, Srinivas R.; Benage, David D.
PUB. DATE
April 2003
SOURCE
American Journal of Gastroenterology;Apr2003, Vol. 98 Issue 4, p939
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
No abstract available.
ACCESSION #
9658123

 

Related Articles

  • Infliximab for Crohn's disease. ROSE, VERNA L. // American Family Physician;12/1/1998, Vol. 58 Issue 9, p2175 

    Introduces the monoclonal antibody, infliximab (Remicade), use for the treatment of Crohn's disease. Mechanism of action; Clinical trials; Side effects.

  • First treatment approved for Crohn's disease.  // FDA Consumer;Nov/Dec98, Vol. 32 Issue 6, p3 

    Reports on the licensing of Remicade (infliximab), a treatment for Crohn's disease from Centocor Inc. Information on Crohn's disease; Composition of the product; Details on the clinical trials of the treatment; Side effects of the treatment.

  • A Breakthrough In Treating Crohn's Disease. Cerrato, Paul L. // RN;Nov98, Vol. 61 Issue 11, p92 

    Focuses on the United States Food and Drug Administration's approval of Infliximab (Remicade) for the treatment of Crohn's disease. How the genetically engineered antibody drug works; Adverse effects of the drug.

  • Crohn's disease.  // Geriatrics;Dec98, Vol. 53 Issue 12, p16 

    Announces that Infliximab (Remicade), an intravenous (IV) injectable chimeric Immunoglobulin Gamma (IgG) monoclonal antibody, was approved for the treatment of Crohn's disease. Recommended dose; Most common side effects.

  • Pneumocystis Jirovecii Pneumonia Complicating Treatment With Infliximab. Fahy, Ruairi J.; Diaz, Philip T. // Internet Journal of Pulmonary Medicine;2006, Vol. 6 Issue 2, p5 

    Blockade of TNF-a using tumor necrosis factor-a antibodies is used in the management of a number of chronic inflammatory diseases and is indicated for treatment of refractory Crohn's Disease. We report the development of Peumocystis Jirovecii (Carinii) pneumonia and acute respiratory failure in...

  • Remicade Approved for Children With Crohn's Disease.  // FDA Consumer;Jul/Aug2006, Vol. 40 Issue 4, p6 

    The article provides information on Remicade (infliximab), a drug approved by the U.S. Food and Drug Administration (FDA) to treat children with active Crohn's disease, a chronic inflammatory condition of the bowel that can be severely debilitating. Remicade is a genetically engineered...

  • Re: Triantafillidis et al.--Acute Idiopathic Pancreatitis Complicating Active Crohn's Disease: Favorable Response to Infliximab Treatment. Fefferman, David S.; Alsahli, Mazen; Lodhavia, Parag J.; Shah, Samir A.; Farrell, Richard J. // American Journal of Gastroenterology;Aug2001, Vol. 96 Issue 8, p2510 

    Presents a letter to the editor about a patient with Crohn's disease complicated by acute idiopathic pancreatitis that improved after treatment with infliximab.

  • Infliximab.  // Reactions Weekly;10/1/2011, Issue 1371, p21 

    The article describes the case of a 74-year-old man who developed seizure after treatment with infliximab for Crohn's disease.

  • Infliximab.  // Reactions Weekly;5/15/2010, Issue 1301, p29 

    The article describes the case of two men who developed fulminant legionellosis after being given infliximab as treatment for Crohn's disease.

  • Crohn's Disease. Lewis, Carol // FDA Consumer;Sep/Oct99, Vol. 33 Issue 5, p26 

    Provides information on Crohn's disease. Signs and symptoms; Treatment; Effectiveness of Remicade, a genetically engineered antibody; Diagnosis; Treatment; Diet.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics